Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea

Clinical Therapeutics

Volumn 31, Issue 5, 2009, Pages 1105-1115

  Sohn, Hyun Soon ^a   Lee, Tae Jin ^b   Kim, Jinhyun ^c   Kim, Donghwan ^d  

^a RUTGERS UNIVERSITY   (United States)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Hallym University College of Medicine   (South Korea)

Author keywords

cost effectiveness; fluconazole; hematopoietic stem cell transplantation; invasive fungal infection; micafungin; prophylaxis

Indexed keywords

FLUCONAZOLE; MICAFUNGIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INVASIVE MYCOSIS; KIDNEY FUNCTION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MEDICAL CARE; MORTALITY; MYCOSIS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SOUTH KOREA;

ADULT; ANTIFUNGAL AGENTS; CHEMOPREVENTION; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION TREES; ECHINOCANDINS; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KOREA; LIPOPEPTIDES; MYCOSES; ODDS RATIO; TREATMENT OUTCOME;

EID: 66949167401     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.05.011     Document Type: Article

References (24)

1. Korea Stem Cell Transplantation Nurses Association. 2005 Current Status of HSCT in Korea. http://www.bmtnurse.org Accessed July 12, 2007
2. Hamza N.S., Ghannoum M.A., and Lazarus H.M. Choices aplenty: Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 34 (2004) 377-389
3. Park S.H., Choi S.M., Lee D.G., et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci. 21 (2006) 199-207
4. Yoo J.H., Lee D.G., Choi S.M., et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 34 (2004) 497-504
5. Leather H.L., and Wingard J.R. Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am 15 (2001) 483-520
6. Moeremans K., Annemans L., Ryu J.S., et al. Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea. Int J Hematol 82 (2005) 251-258
7. Oren I., Rowe J.M., Sprecher H., et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38 (2006) 127-134
8. Yoo J.I., Choi C.W., Lee K.M., et al. National surveillance of antifungal susceptibility of Candida species in South Korean hospitals. Med Mycol 25 (2008) 1-5
9. van Burik J.H., Ratanatharathorn V., Stepan D.E., et al., the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 39 (2004) 1407-1416
10. Korea Food and Drug Administration. Drug Information. http://ezdrug.kfda.go.kr Accessed March 15, 2008
11. Ascicoglu S., Rex J.H., De Pauw B., et al. Defining opportunistic invasive fungal infections in immunocom-promised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis. 34 (2007) 7-14
12. Min C.K., Jeong W., Park S.J., et al. Stem cell transplantation in adult acute lymphoblastic leukemia. Korean J Hematopoietic Stem Cell Transplant 4 (1999) 161-172
13. Korea National Statistical Office. 2005 Life Tables of Korean Population. http://www.kosis.kr Accessed March 20, 2007
14. Briggs A., Claxton K., and Sculpher M. Decision Modeling for Health Economic Evaluation (2006), Oxford University Press, New York, NY
15. 2005 National Health Insurance and Medicaid Data (2006), Health Insurance Review Agency, Seoul, Korea
16. Health Insurance Review and Assessment Service. The NHI drug formulary and price list 2007. http://www.kpis.or.kr/index.jsp Accessed December 13, 2007
17. Health Insurance Review and Assessment Service. Quantity-weighted average price by individual drug ingredient and dosage form. http://www.kpis.or.kr/index.jsp Accessed December 13, 2007
18. Korea National Statistical Office. The Consumer Price Index (2007). http://www.kosis.kr Accessed December 13, 2007
19. Korea Hosptial 2005 Quarter 4 (2006), IMS Data, Seoul, Korea
20. Lee D.-G., Song Y.-G., Yoo J.-H., et al. Cost-identification analysis between amphotericin B deoxycholate and intravenous itraconazole in the empirical treatment of febrile neutropenic patients: Preliminary report. J Infect Chemother 36 (2004) 304-310
21. Stewart A., Powles R., Hewetson M., et al. Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal ampho-tericin and oral polyenes as prophylaxis against oropharyngeal infections. PharmacoEconomics 8 (1995) 350-361
22. Nomura K., Kawasugi K., and Morimoto T. Cost-effectiveness analysis of an-tifungal treatment for patients on chemotherapy. Eur J Cancer Care (Engl) 15 (2006) 44-50
23. Cross S.A., and Scott L.J. Micafungin: A review of its use in adults for the treatment of invasive and oesopha-geal candidiasis, and as prophylaxis against Candida infections. Drugs 68 (2008) 2225-2255
24. Cornely O.A., Sidhu M., Odeyemi I., et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 24 (2008) 1743-1753